Literature DB >> 17123310

Mutant p53 proteins: between loss and gain of function.

Sabrina Strano1, Stefania Dell'Orso, Adriana Maria Mongiovi, Olimpia Monti, Eleonora Lapi, Silvia Di Agostino, Giulia Fontemaggi, Giovanni Blandino.   

Abstract

Cancer might result from both the aberrant activation of genes, whose physiological tuning is essential for the life of a normal cell, and the inactivation of tumor suppressor genes, whose main job is to preserve the integrity of cell genome. Among the latter, p53 is considered a key tumor suppressor gene that is inactivated mainly by missense mutations in half of human cancers. It is becoming increasingly clear that the resulting mutant p53 proteins gain oncogenic properties favoring the insurgence, the maintenance, and the spreading of malignant tumors. In this review, we mainly discuss the molecular mechanisms underlying gain of function of human tumor-derived p53 mutants, their impact on the chemoresistance and the prognosis of human tumors, with a special focus on head and neck cancers, and the perspectives of treating tumors through the manipulation of mutant p53 proteins. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17123310     DOI: 10.1002/hed.20531

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  19 in total

Review 1.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

2.  Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta.

Authors:  Aditi Chatterjee; Xiaofei Chang; Tanusree Sen; Rajani Ravi; Atul Bedi; David Sidransky
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

Review 3.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

4.  Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships.

Authors:  Xiantao Wang; Anthony J Di Pasqua; Sudha Govind; Erin McCracken; Charles Hong; Lixin Mi; Yuehua Mao; Jessie Yu-Chieh Wu; York Tomita; Jordan C Woodrick; Robert L Fine; Fung-Lung Chung
Journal:  J Med Chem       Date:  2011-01-11       Impact factor: 7.446

5.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

6.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Authors:  Yunqing Li; Fadila Guessous; Sherwin Kwon; Manish Kumar; Opeyemi Ibidapo; Lauren Fuller; Elizabeth Johnson; Bachchu Lal; Isa Hussaini; Yongde Bao; John Laterra; David Schiff; Roger Abounader
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

7.  Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

Authors:  F Ganci; A Sacconi; N Bossel Ben-Moshe; V Manciocco; I Sperduti; L Strigari; R Covello; M Benevolo; E Pescarmona; E Domany; P Muti; S Strano; G Spriano; G Fontemaggi; G Blandino
Journal:  Ann Oncol       Date:  2013-10-09       Impact factor: 32.976

Review 8.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

9.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

Authors:  Ken H Young; Karen Leroy; Michael B Møller; Gisele W B Colleoni; Margarita Sánchez-Beato; Fábio R Kerbauy; Corinne Haioun; Jens C Eickhoff; Allen H Young; Philippe Gaulard; Miguel A Piris; Terry D Oberley; William M Rehrauer; Brad S Kahl; James S Malter; Elias Campo; Jan Delabie; Randy D Gascoyne; Andreas Rosenwald; Lisa Rimsza; James Huang; Rita M Braziel; Elaine S Jaffe; Wyndham H Wilson; Louis M Staudt; Julie M Vose; Wing C Chan; Dennis D Weisenburger; Timothy C Greiner
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

10.  Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice.

Authors:  Nicholas A Bosma; Arvind K Singla; Charlene M Downey; Frank R Jirik
Journal:  Oncoscience       Date:  2014-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.